Reyes CY, Zaila LE, Aquino PA, Rodríguez MG, Aquino RAA, Herrera MG

Language: Spanish
References: 14
Page: 16-25
PDF size: 228.20 Kb.

ABSTRACT

Background: Protein electrophoresis and serum free light chains are techniques used in the diagnosis of multiple myeloma. However, the diagnostic utility of both tests may vary according to the method used and the actual conditions of the environment where they are performed.
Objective: To determine the diagnostic value of protein electrophoresis and serum free light chains in multiple myeloma.
Methodology: A retrospective study of serum protein electrophoresis parameters and serum free light chains was conducted in 43 patients diagnosed with multiple myeloma by bone marrow evaluation. Protein electrophoresis was completed by the conventional method of protein separation on cellulose acetate paper and for free light chains an immunoturbidimetric assay was applied in which a chemical analyzer (Cobas 311) was used. Seven parameters were calculated to evaluate diagnostic accuracy.
Results: All parameters assessing diagnostic accuracy were within confidence intervals in both tests.
Conclusions: Protein electrophoresis and serum free light chains are very useful assays in the diagnosis of multiple myeloma and should be used in conjunction for the highest possible approval of cases.

REFERENCES

1. Kumar SK, Rajkumar V, Kyle RA, van Duin M, Sonneveld P, Mateos M-V, et al. Multiple myeloma. Nat Rev Dis Primer [Internet]. 2017 [cited 2020 Jul 28];10:1-21. Available from: Available from: https://www.frontiersin.org/articles/10.3389/fonc.2020.01243/full

2. Singh G. Oligoclonal Pattern/Abnormal Protein Bands in PostTreatment Plasma Cell Myeloma Patients: Implications for Protein Electrophoresis and Serum Free Light Chain Assay Results. J Clin Med Res [Internet]. 2017 [cited 2020 Jul 28];9(8):671-9. Available from: Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5505303/pdf/jocmr-09-671.pdf

3. Mesa Sierra M, Jaramillo Arbeláez PE, Diaz L, Galvez K. Cadenas ligeras libres en suero en el diagnóstico de Gammapatías Monoclonales. Rev Avances en Salud [Internet]. 2019 [citado 15 Ene 2021];153(2):42-53. Disponible en: Disponible en: https://revistas.unicordoba.edu.co/index.php/avancesalud/article/view/1861/2267

4. Singh G. Serum Free Light Chain Assay and К/λ Ratio: Performance in Patients With Monoclonal Gammopathy-High False Negative Rate for К/λ Ratio. J Clin Med Res [Internet]. 2017 [cited 2020 Jan 15];9(1):46-57. Available from: Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5127215/pdf/jocmr-09-046.pdf

5. Singh G. Serum Free Light Chain Assay and j/k Ratio Performance in Patients Without Monoclonal Gammopathies High False-Positive Rate. Am J Clin Pathol [Internet]. 2016 [cited 2020 Jan 15];146(2):207-14. Available from: Available from: https://academic.oup.com/ajcp/article/146/2/207/1730908

6. Singh KK, Silverman M, Farooq U, Tricot A, Dozeman L, Nadiminti K, et al. Potential pitfalls of serum free light chain analysis to assess treatment response for multiple myeloma. Br J Hematol [Internet]. 2016 [cited 2020 Jan 15];174(4):536-40. Available from: Available from: https://onlinelibrary.wiley.com/doi/epdf/10.1111/bjh.14081

7. Heaney J, Campbell JP, Yadav P, Griffin AE, Shemar M, Pinney JH, et al. Multiple myeloma can be accurately diagnosed in acute kidney injury patients using a rapid serum free light chain test. BMC Nephrology [Internet]. 2017 [cited 2020 Jul 28];18(1):2-8. Available from: Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520226/pdf/12882_2017_Article_661.pdf

8. Díaz-García L, Medina-Vera I, García-de la Puente S, González-Garay A, Murata C. Estudios de exactitud diagnóstica. Acta Pediatr Mex [Internet]. 2019 [citado 2020 Ene 15];40(6):342-57. Disponible en: Disponible en: https://www.medigraphic.com/pdfs/actpedmex/apm-2019/apm196e.pdf

9. Revethan R. Sensitivity, Specificity, and Predictive Values: Foundations, Pliabilities, and Pitfalls in Reearch and Practice. Front Public Health [Internet]. 2017 [cited 2020 Jan 15];5. Available from: Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5701930/pdf/fpubh-05-00307.pdf

10. Pizarro R, Samanez C, Cartolin M, Delgado F. Efecto de la medición de cadenas ligeras libres en suero en el diagnóstico de gammapatías monoclonales; experiencia en Perú. Rev Hematol Mex [Internet]. 2016 [citado 15 Ene 2021];17(2):99-106. Disponible en: www.medigraphic.com/pdfs/hematologia/re-2016/re162e.pdf

11. Dejoie T, Corre J, Caillon H, Hulin C, Perrot A, Caillot D, et al. Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma. Blood [Internet]. 2016 [cited 2020 Jan 15];128(25):2941-8. Available from: Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5179336/

12. Pedroza Vázquez A, Zamora Palma A. Utilidad de pruebas de laboratorio en el diagnóstico de mieloma múltiple. Rev Mex Patol Clin Med Lab [Internet]. 2015 [citado 15 Ene 2021];62(1):55-62. Disponible en: Disponible en: https://www.medigraphic.com/pdfs/patol/pt-2015/pt151i.pdf

13. Singh G. Serum and Urine Protein Electrophoresis and Serum-Free Light Chain Assays in the Diagnosis and Monitoring of Monoclonal Gammopathies. J Appl Lab Med [Internet]. 2020 [cited 2020 Dec 20];5(6):1358-71. Available from: Available from: https://pubmed.ncbi.nlm.nih.gov/33150391

14. Lippi G, Mattiuzzi C. The biomarker paradigm: between diagnostic efficiency and clinical efficacy. Pol Arch Med Wewn [Internet]. 2015 [cited 2020 Dec 20];125(4):282-8. Available from: Available from: http://pamw.pl/en/node/2788/pdf